P2X7-blocking nanobodies

P2X7-blocking nanobodies are single-domain antibody fragments (VHHs) designed to target and inhibit the P2X7 receptor, an ATP-gated ion channel that acts as a key sensor of sterile inflammation. Developed by researchers at the University Medical Center Hamburg-Eppendorf (UKE) in collaboration with Ablynx, these nanobodies (such as clones 13A7, 1c81s, and Dano1) block P2X7 activation, preventing downstream signaling cascades including calcium influx, pore formation, and the release of proinflammatory cytokines like interleukin-1 beta (IL-1β). They have shown therapeutic potential in preclinical models of glomerulonephritis, allergic contact dermatitis, stroke, and graft-versus-host disease (GVHD).

Other names

P2X7-antagonistic nanobodiesP-2X7-antagonistic nanobodiesP 2X7-antagonistic nanobodiesP2X7-specific nanobodiesP-2X7-specific nanobodiesP 2X7-specific nanobodiesanti-P2X7 VHHsanti-P-2X7 VHHsanti-P 2X7 VHHsanti-P2X7 nanobodiesanti-P-2X7 nanobodiesanti-P 2X7 nanobodies